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ABSTRACT Binding of transcriptional activators to a
promoter is a prerequisite process in transcriptional activa-
tion. It is well established that the efficiency of activator
binding to a promoter is determined by the affinity of direct
interactions between the DNA-binding domain of an activator
and its specific target sequences. However, I describe here that
activator binding to a promoter is augmented in vivo by the
effects of two other determinants that have not been generally
appreciated: (i) the number of activator binding sites present
in a promoter and (ii) the potency of activation domains of
activators. Multiple sites within a promoter can cooperatively
recruit cognate factors regardless of whether they contain an
effective activation domain. This cooperativity can result in
the synergistic activation of transcription. The second effect
is the enhancement of activator binding to a promoter by the
presence of activation domains. In this case, activation do-
mains are not simply tethered to the promoter by the DNA-
binding domain but instead assist the DNA-binding domain
being tethered onto the promoter. This effect of activation
domains on DNA binding is instrumental in determining how
potent activators can induce steep transcriptional increases at
low concentrations.
Activation of transcription in eukaryotes is a complex process,
involving numerous molecular interactions between compo-
nents such as transcriptional activator proteins, general tran-
scriptional factors, and promoter DNA (for reviews, see refs.
1-4). Levels of activation can be modulated by variations in
these interactions, resulting from changes in diverse parame-
ters such as promoter structure (e.g., the number of activator-
binding sites), activator properties (e.g., activation potency),
and cellular environment (e.g., activator concentration). In-
deed, it is the combined effects of many parameters such as
these that ultimately determine the level of transcription of a
gene under a given cellular circumstance.
The combined effects of these multiple parameters have
been investigated in vivo in diverse systems (5-10). While the
results of these studies have shown that transcriptional effects
caused by changes in these various parameters are often
interdependent (5-10), they have recurrently revealed one
important aspect in transcriptional regulation-synergistic
transcriptional responses to parameter changes. Thus, an
increase in the number of activator-binding sites often results
in synergistic increases in transcription (5, 8-10), and a mod-
erate increase in activator concentration can induce steep
transcriptional responses (6).
In theory, the levels of transcription from a promoter can be
modulated by either changes in the levels of activator binding
to a promoter or changes in the efficacy of the promoter-bound
activators to give rise to distinct transcriptional outcomes (e.g.,
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synergistic transcriptional increases). In the case of the yeast
GAL4 activator, it was shown that cooperative activator
binding to a promoter is predominantly responsible for syn-
ergistic transcriptional activation by multiple activator-binding
sites (5). It is not generally known, however, if alterations in
transcriptional outcomes are produced through differences in
either activator binding or stimulation of transcription by
promoter-bound activators. To investigate further the mech-
anism through which the effects of multiple parameters are
integrated on a promoter to produce specific transcriptional
outcomes in yeast cells, I have studied the effects of varying
three selected parameters-(i) the number of activator binding
sites present in a promoter, (ii) activation potency of activators,
and (iii) activator concentration-on both transcriptional ac-
tivator binding to a promoter and transcription from the
promoter in vivo. This analysis revealed that activator binding
to promoter DNA is modulated in vivo by both the number of
binding sites and activation potency of activators, emphasizing
this DNA-binding step as a key regulatory point in transcrip-
tional activation.
MATERIALS AND METHODS
Plasmids and Yeast Strains. Reporter plasmids were de-
rived from the plasmid pJP160 (provided by R. J. Reece, J.
Pearlberg, and M. Ptashne, Harvard University, Cambridge,
MA), and contained one, two, or six tandem copies of the
octamer binding sites (11), the CYC1 promoter segment (-67
to +49; +1 corresponds to the most upstream transcription
initiation site; ref. 12) upstream of the Escherichia coli lacZ
reporter gene. Yeast reporter strains were produced by inte-
grating the yeast reporter plasmids into the genome of Sac-
charomyces cerevisiae YPH499 (13). The effectors contained
the epitope tag and the nuclear localization signal (Met-Ser-
Ser-Tyr-Pro-Pro-Tyr-Asp-Val-Pro-Asp-Tyr-Ala-Ser-Leu-Gly-
Gly-Pro-Ser-Ser-Pro-Pro-Lys-Lys-Lys-Lys-Lys-Arg-Lys-Val-
Ser-Ser; refs. 14 and 15), followed by the Oct-2 POU-domain
sequence (195-357 in the Oct-2 amino acid sequence; ref. 16)
and various transcriptional activation domains. These activa-
tion domains were produced by tandemly reiterating small
subsegments within the activation domain of the herpes sim-
plex virus activator VP16 (17-19) (see Figs. 1 and 3 for the
amino acid sequences of each segment). The coding sequence
was cloned into the plasmid pRS305 (13), together with the
flanking GALl promoter and ADH1 terminator sequences
(20), to produce effector plasmids. These effector plasmids
were integrated into the genome of the yeast reporter strains
described above.
In Vivo Dimethyl Sulfate (DMS) Methylation Protection
Assay. Yeast cells were treated with 30 mM DMS at 30°C for
5 min, followed by extraction of genomic DNA. The extracted
DNA was subjected to piperidine treatment, primer extension,
Abbreviation: DMS, dimethyl sulfate.
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and ligation-mediated PCR amplification, followed by an
additional primer-extension reaction with an end-labeled
primer that annealed upstream of the octamer site(s) (21, 22).
Extents of in vivo site occupancy by activators were calculated
from ratios of band intensity of protected guanine residues
(indicated by filled triangles in Fig. 2a) to reference guanine
residues, which produced bands immediately below each pro-
tected guanine residues (see also Fig. lb). The band intensity
was quantitated with Fujix bio-imaging analyzer BAS1000.
Immunoblot and p-Galactosidase Assays. Protein samples
were prepared in Laemmli sample buffer (23) and analyzed by
SDS/PAGE, followed by immunoblot analysis. The blot was
probed with the YS123 monoclonal antibody (provided by W.
Herr, Cold Spring Harbor Laboratory, Cold Spring Harbor,
NY), which recognizes the Oct-2 POU domain, and the signals
were detected by enhanced chemiluminescence (Amersham).
Levels of activators were determined by comparing band
intensity of experimental samples to quantitation standards,
which contained E. coli-expressed Oct-2 POU-domain protein
serially diluted two-fold in mock yeast extracts. The band
intensity was quantitated with IS-1000 digital imaging system
(Alpha Innotech, San Leandro, CA). The 13-galactosidase
activity was assayed according to a published procedure (24).
RESULTS
Experimental Design. Fig. 1 depicts the experimental sys-
tem. A set of transcriptional activators were produced (Fig. la)
by fusing the mammalian Oct-2 POU DNA-binding domain
(16) to tandemly reiterated copies of an 8-aa activation module
(referred to here as the VN8 module) derived from the herpes
simplex virus transactivator VP16 (17-19). This reiteration
strategy allowed modulation of activation potency by varying
the number of VN8 modules without introducing a qualitative
alteration in activation-domain function; activators with in-
creasing number of reiterated VN8 module activated transcrip-
tion more efficiently, whereas the POU domain alone, al-
though selectively localized in the nucleus, did not activate
transcription efficiently (see below; and data not shown). The
VN8 module was one of the most potent in activating tran-
scription among several tested (e.g., see Fig. 3), yet it had no
effect on yeast cell growth under the experimental conditions
described in the present work. To modulate activator concen-
tration, expression of these POU-domain-containing activa-
tors was regulated with the inducible GALl promoter (Fig. la).
Finally, to examine the effects of the number of activator-
binding sites in a promoter, a set of test promoters, which
contained one, two, or six tandem copies of the Oct-2 POU-
domain-binding site (the octamer sequence), were fused up-
stream of the E. coli lacZ reporter gene (Fig. lb). For each
combination of activator potency, concentration, and number
of binding sites, the levels of transcriptional activation were
determined by quantitating expression of the E. coli lacZ
reporter gene. In parallel, binding of the activators to their
cognate sites was examined in vivo by DMS methylation
protection assay; a guanine residue within the octamer motif
was specifically protected from methylation by binding of
POU-domain proteins both in vivo and in vitro (see below; and
data not shown).
Cooperative Activator Binding to Multiple Sites in a Pro-
moter in Vivo. Fig. 2a displays the result of the in vivo
DNA-binding analysis. Each activator was expressed at three
different levels, as detected by immunoblot analysis (Fig. 2b),
and assayed on the lx, 2x, or 6x site test promoters. In this
analysis, different activators were expressed specifically at
levels that produced similar extents of site occupancy in vivo.
A comparison of promoters containing different numbers of
sites revealed that for all the effector proteins-regardless of
whether they contained an activation domain-in vivo site
occupancy was greater for the 6x site promoter than for the
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FIG. 1. Effectors and reporters. (a) The Oct-2 POU domain was
fused at its C-terminus to either a stop codon or to reiterated copies
of the VN8 activation module. The activator-encoding sequences were
placed downstream of the regulatable GALl promoter. (b) The
reporter-gene promoter contained the CYC1 TATA boxes and one,
two, or six tandem copies of a sequence containing a canonical
octamer sequence (shaded) derived from the human histone H2B
promoter (shown by uppercase letters in the DNA sequence) fused
upstream of the E. coli P3-galactosidase reporter gene. The filled
triangle below the DNA sequence indicates the guanine residue that
was protected by the POU-domain proteins from DMS modification.
The open triangle indicates the guanine residue used as a reference for
quantitations (see Fig. 2).
2x site promoter (e.g., compare lanes 19-21 to lanes 15-17 in
Fig. 2 a and b). In contrast, all the effectors failed to bind
effectively to the lx site promoter (lanes 11-13, 23-25, and
35-37; see also a quantitation in Fig. 2c). This result demon-
strates that activator binding is augmented by the number of
binding sites present in a promoter, indicating that activators
cooperatively bind to their cognate sequences in vivo, and,
further, that this cooperativity does not require the presence
of an effective activation domain.
Enhancement of Activator Binding to Promoters by Tran-
scriptional Activation Domains in Vivo. In contrast to the
activation domain-independent effects of multiple binding
sites, a comparison among activators of different potencies
revealed that activator binding to a promoter in vivo is
augmented by the presence of activation domains (Fig. 2). For
example, to achieve relatively similar levels of binding to the
2x site promoter in vivo (Fig. 2a, lanes 15-17, 27-29, and
39-41), the DNA-binding domain alone required significantly
higher levels of expression (lanes 15-17 in Fig. 2b) than either
the strong 6x VN8 (lanes 39-41 in Fig. 2b) or weak 2x VN8(lanes 27-29 in Fig. 2b) activators. Indeed, quantitation of
these results (Fig. 2c; note that scales of horizontal axes in the
graphs vary) revealed that, with the 2x site promoter, the
activator with the 6x VN8 activation domain (the right graph)
occupied the cognate sites at 30-fold lower concentrations than
4312 Bohmsr:Tnk
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FIG. 2. In vivo site occupancy and induction of reporter-gene expression by activator proteins. (a) In vivo site occupancy by activators. Products
of G-specific cleavages of yeast DNA, methylated in vivo by DMS, are shown. Positions of protected guanine residues (filled triangles; see also Fig.
lb) are indicated at right. The figure consists of four three-panel sets; three panels within each set show the results with the lx, 2X, and 6x site
promoters, as indicated. The first three-panel set (lanes 1-9) shows the results with negative control samples, which contained either yeast DNA
methylated by DMS in vitro (lanes 1, 4, and 7) or methylated in vivo in the absence of effector expression. These in vivo-methylated control samples
were prepared from cells that contained an empty vector and were grown in a medium supplemented with glucose (lanes 2, 5, and 8) or a
galactose/glucose (0.324/0.676) mixture (lanes 3, 6, and 9). The remaining three three-panel sets show experimental results with the POU
DNA-binding domain alone (lanes 10-21) and the 2x VN8 (lanes 22-33) and 6x VN8 activators (lanes 34-45). Each panel here consists of four
lanes; the first lane of each panel is a duplicate of the appropriate negative control sample (i.e., lane 3, 6, or 9), and the following three lanes contain
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the DNA-binding domain alone (the left graph), whereas the
weak 2x VN8 activation domain also showed a significant,
although moderate, 3-fold effect on DNA binding (the center
graph). These results indicate that the DNA-binding domain is
not the sole determinant of DNA binding, but that activation
domains significantly facilitate activator binding to their cog-
nate sites in vivo. In contrast to these in vivo results, neither the
presence of activation domains nor the number of binding sites
augmented activator binding to their cognate sites in a typical
in vitro assay (data not shown).
Effect of Cooperative DNA Binding on Transcriptional
Activation in Vivo. The transcriptional effects of modulating
activator binding in vivo are illustrated in Fig. 2d. A compar-
ison among different promoters revealed that the 2x site
promoter directs 10-fold higher levels of transcription than the
1 x site promoter with either the weak 2x VN8 activator (the
center graph in Fig. 2d) or strong 6x VN8 activator (the right
graph), irrespective of activator concentrations. This 10-fold
increase in transcription-regardless of either activation po-
tency or concentration-is indicative of activation-domain-
independent cooperativity in DNA binding. Nevertheless, the
present analysis does not demonstrate whether this coopera-
tive binding is exclusively responsible for the increases in
transcription, because transcriptional activity of the 1 x and 2x
site promoters when bound by activators could not be com-
pared due to poor activator binding to the lx site promoter
(see Fig. 2c).
Comparison of the transcriptional efficacy of activator-
bound promoters, however, was possible between the 2x and
6x site promoters. This comparison revealed that, at similar
levels of in vivo occupancy by the 2x VN8 activator, these two
promoters direct similar levels of transcription (Fig. 2e; the
center graph). Thus, the 6x site promoter achieves higher
levels of transcription than the 2x site promoter at equivalent
activator concentrations (Fig. 2d; the center graph) predom-
inantly because the activator is more readily recruited to the
6x site promoter than to the 2x site promoter (Fig. 2c; the
center graph). In this case, differential transcriptional re-
sponses of promoters that contain different numbers of sites
are generated primarily through differential activator binding,
whereas the transcriptional efficacy of the promoters when
bound by the activator is nearly unchanged.
Effects of Activation Domains on Transcriptional Re-
sponses. The transcriptional responses displayed in Fig. 2 d and
e also illuminate the significance of activation-domain function
in augmenting transcription in vivo. First, a comparison of the
transcriptional activity of promoter-bound activators (Fig. 2e;
note that scales of vertical axes in the graphs vary) indicates
that the strong 6x VN8 activator (the right graph) achieves
4-fold higher levels of transcription than the weak 2x VN8
activator (the center graph), whereas the promoter-bound
DNA-binding domain (the left graph) is virtually inactive. This
in vivo result substantiates a generally assumed function of
activation domains-namely, that activation domains, when
brought to a promoter, stimulate transcription to different
extents depending on their potencies.
However, whereas this function of activation domains is
required to exert transcriptional effects, it is not necessarily the
major determinant of differential transcriptional activation by
different activators. With the 2X site promoter, for example,
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FIG. 3. Comparing the ability of various activation domains to
enhance DNA binding and to stimulate transcription in vivo. (Left)
Structures of activation domains, composed of reiterated copies of
wild-type and mutant (mutant residues indicated by white letters) VN8
module and other VP16-derived activation modules; each was fused to
the Oct-2 POU DNA-binding domain. These activators were assayed
for their levels of expression, in vivo site occupancy, and transcriptional
activation with the 2x site promoter as described for Fig. 2. (Right)
Results of these assays; the upper graph shows levels of activators
required for half-optimal site occupancy in vivo, and the lower graph
shows respective levels of transcription. Plotted values were obtained
either from a single data point, which displayed near half-optimal site
occupancy (46-53% protection), or from the interpolation of a pair of
data points, one of which displayed site occupancy lower than half-
optimal (29-40% protection) and the other displayed site occupancy
higher than half-optimal (58-65% protection). In the latter cases,
actual levels of activators and transcription from these pairs of data
points are shown as upper and lower limits of error bars.
the 6x VN8 activator achieves 40-fold higher levels of tran-
scription than the 2x VN8 activator relative to activator levels
(Fig. 2d; compare the right and center graphs). This 40-fold
difference in the steepness of transcriptional responses can be
attributed to both (i) the 4-fold difference in transcriptional
activation by promoter-bound activators (Fig. 2e), and (ii) the
10-fold difference in activator binding to the promoter (Fig.
2c). In addition to the previous 2x and 6x site promoter
comparison, this result represents another example of differ-
ential transcriptional responses that are produced, in a large
part, through differential activator binding; in this case, how-
ever, differential binding is caused by the differential ability of
activation domains to enhance DNA binding.
Correlation Between Abilities of Activation Domains to
Enhance DNA Binding and to Stimulate Transcription. The
correlation between the abilities of activation domains to
enhance DNA binding and to stimulate transcription was
further investigated with an array of different activators; these
activators contained activation domains composed of reiter-
ated wild-type or mutant VN8 modules or other VP16 activa-
tion modules (Fig. 3). The results displayed in Fig. 3 show the
levels of each of these activators required for half-optimal site
samples that were prepared from cells expressing three different levels of effectors (see b). These cells were grown in a medium supplemented with
a galactose/glucose mixture of various galactose/glucose ratios (0.012-0.324). (b) Expression of effectors. Protein extracts were prepared from
portions of yeast-cell samples described in a, and effector expression was detected from 10 ,ug of yeast protein by immunoblot analysis. Quantitations
of the results are illustrated in three graphs: c, extents of site occupancy in vivo versus levels of activator expression; d, levels of lacZ reporter-gene
(/3-Gal) expression versus levels of activator expression; and e, levels of lacZ reporter-gene expression versus extents of site occupancy in vivo. The
left, center, and right graphs show the results with the DNA-binding domain alone (POU), and the 2x VN8 and 6x VN8 activators, respectively;
in each graph, the results with the 1 x, 2 X, and 6x site promoters are indicated by open, crossed, and filled symbols, respectively. Note that scales
of some axes were varied, as indicated by different shadings.
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occupancy in vivo on the 2x site promoter (the upper graph)
and the resulting transcriptional activation (the lower graph).
This analysis revealed that activators that are more efficient in
DNA binding (i.e., those shown toward the right in the graphs
in Fig. 3) are generally more efficient in transcription when
bound to the promoter. This result indicates that the ability to
enhance DNA binding and to stimulate transcription coincides
within these various different small activation modules, and,
furthermore, it shows that the strength of the two activities
correlate with one another.
DISCUSSION
A pioneering study by Giniger and Ptashne (5) previously
showed that the potent yeast activator GAL4 binds coopera-
tively to two adjacent sites in vivo. I have described here that
activator binding to a promoter is augmented by both activa-
tion-domain-independent cooperativity and an activation-
domain-mediated effect. It has been also reported that, in the
case of the yeast Pho4 activator, the presence of an activation
domain is apparently required for it to bind to the PH05
promoter and to disrupt nucleosomes (25). In a typical in vitro
assay, in contrast, neither the number of binding sites nor the
potency of activation domains effected on DNA binding of
yeast-expressed POU-domain activators (data not shown).
Therefore, binding of these POU-domain activators to pro-
moters must be governed in vivo not only by the direct
interaction between the DNA-binding domain of activators
and specific target sequences but also by other interactions that
specifically facilitate binding of potent activators to multiple
sites. Because cooperative activator binding does not require
the presence of effective activation domains, these other
interactions constitute two different pathways in modulating
activator binding to their cognate sites in vivo: a pathway
responsible for activation-domain-independent cooperative
binding, which perhaps takes effect preceding stimulation of
transcription, and a second pathway responsible for activation-
domain-mediated enhancement of activator binding.
The comparison of various different activation domains
revealed correlations between their effects on DNA binding
and transcription (Fig. 3). Therefore, in producing these two
effects, activation domains may rely on interactions either with
an identical target(s) or, alternatively, with different targets
that similarly distinguish different activation domains. In con-
trast, I have found that the transcriptional effect, but not the
DNA-binding effect, of activation domains was diminished by
a mutation in the TATA box of a test promoter (unpublished
data), suggesting discrete pathways to exert the two effects.
Moreover, some in vitro studies that use nucleosomal DNA
have revealed that histones and regulatory factors such as
SWI/SNF proteins (for review, see ref. 26), in the absence of
general transcription factors, can modulate activator binding
to DNA in a manner that is responsive not only to the number
of binding sites (27-29) but also to the presence of activation
domains (30). Therefore, although the significance of these in
vitro effects has yet to be verified in vivo, it is possible that
activation domains augment activator binding to DNA and
transcription through diverse pathways yet via a common or
similar target(s).
Transcriptional efficacy of a promoter is determined
through integration of numerous parameters via multitudes of
protein-protein and protein-DNA interactions. In this entire
process, modulation of interactions between promoter-bound
activators and general transcription factors have been broadly
accepted to produce specific transcriptional outcomes from a
promoter. Indeed, by modulating these interactions, potency
of activation domains and the number of binding sites can
impact on transcription in vitro (31, 32). However, the present
work indicates that these parameters significantly affect one
other step of the activation process in vivo-the step of
activator binding to a promoter. In the examples described
here, as well as in another case with GAL4 (5), these effects
on DNA binding are predominantly responsible for different
transcriptional responses. These findings suggest that the step
of activator binding to a promoter plays a more substantial role
than generally realized in sensing the promoter structure and
activator quality/quantity to give rise to a specific transcrip-
tional output from a promoter under a particular cellular
environment.
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